Aurinia Pharmaceuticals Inc. (AUPH) News
Track canonical SquawkNews coverage tagged to AUPH, Aurinia Pharmaceuticals Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Aurinia says Teva generic voclosporin may launch after 2036
Aurinia Pharmaceuticals says Teva may launch a generic version of voclosporin in the U.S. no earlier than December 7, 2036, while patent litigation continues in New Jersey.
REGULATION | Aug 19, 2026, 08:06 PM UTC
L
Aurinia settles U.S. patent litigation with Teva over voclosporin
Aurinia Pharmaceuticals says it has settled patent litigation with Teva over generic voclosporin in the U.S.
REGULATION | Aug 19, 2026, 08:05 PM UTC
L
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ: AUPH ) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
EARNINGS | Aug 06, 2026, 12:41 PM UTC